US Compounding (USC), an Adamis Pharmaceuticals Corp. wholly owned drug outsourcing facility, recently switched its operations to produce medical-grade hand sanitizers for hospitals and health care workers fighting COVID-19.
The switch was in response to Food and Drug Administration (FDA) guidance enabling FDA-registered outsourcing facilities to manufacture alcohol-based hand -sanitizer products for the duration of the public health emergency.
“With demand for hand sanitizer currently outpacing supply, we have moved expeditiously to make these products available,” Dr. Dennis J. Carlo, Adamis president and CEO, said. “We will continue to manufacture for so long as there is a shortage.”
USC typically produces certain nonsterile drugs and compounds used in sterile prescription drugs that are used in hospitals, clinics, and surgery centers nationwide.
The first batches of hand sanitizer will be shipped to hospitals in New York.
Adamis Pharmaceuticals is a specialty biopharmaceutical company focusing primarily on the development and commercialization of therapeutic products, including opioid overdose, allergy, and respiratory disease.
The company is developing a naloxone injection product candidate, ZIMHI, for the treatment of opioid overdose.
The FDA has approved two products, SYMJEPI (epinephrine) Injection 0.3mg and SYMJEPI (epinephrine) Injection 0.15mg, for the emergency treatment of acute allergic reactions. Both were launched in 2019.